To investigate the role of PTPRO in a clinical setting, 24 patients with benign liver conditions who had been diagnosed with NAFLD and were undergoing liver surgery were included in this study (Table 1). The gene discussed is PTPRO; the disease is metabolic dysfunction-associated steatotic liver disease.